Bit of Background These new classes of antiobesity medications (ie, the GLP-1 agonists and dual agonists), referred to in this article as weight management medications, arent really new.1-4 The basic science and pharmaceutical research and development to bring these to market began more than two decades ago when two scientists, Matthias Tschop, MD, and Richard DiMarchi, PhD, hypothesized that the actions of various gut hormones may offer safe and unprecedented weight loss
The practical tradeoffs between the two methods come down to time, customization, and cost
Dual and Triple Agonist Medications The field is evolving rapidly
Standardized protocols can help ensure consistent application of safety measures while allowing flexibility for specific clinical situations
Currently, the respective contributions of alcohol and metabolic factors to liver disease are not elucidated in this population
Thoughtful development not only improves the stability and effectiveness of the formula but also strengthens the brands long-term reputation